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Summary 
We have used an efficient cDNA subtraction library procedure to identify newly induced genes 
in human B lymphocytes infected for 6 h with Epstein-Barr virus (EBV).  Among the genes 
identified by automated sequencing of a random subset of clones from this library,  one coded 
the EBV BCRF1 open reading frame, which specifies the viral interleukin 10 gene (vlL-10). 
This molecule is highly homologous to human (h)IL-10 and was previously thought to represent 
a "late" viral gene expressed only during the lytic phase of virus replication. Using gene amplification 
by reverse transcriptase  polymerase chain reaction of B cell RNA obtained at varying times after 
infection, we detected vlL-10 expression within a few hours of EBV infection, followed, 20-30 h 
later by expression of hlL-10. Expression of both genes continued beyond the initial transformation 
phase (5-10 d) and was present in all transformed cell lines  tested. When added at the time 
of viral infection, antisense (but not sense) oligonucleotides for vlL-10 mRNA (cytosolic half- 
life, '~6 h) prevented subsequent B cell transformation. The antisense effect was highly specific, 
leaving the expression levels of other transformation-related genes intact. Addition of exogenous 
(h)IL-10 rescued the transformation process in antisense-treated cells. Our observations establish 
vlL-10 as a new latency gene with a directly transformation-prerequisite function. 
E 
BV is a highly prevalent herpes virus associated with a 
growing number of lymphatic and epithelial malignan- 
cies (1-9).  Lymphocytes (mainly of B cell lineage)  that ex- 
press the CD21 EBV receptor (10) are effidently growth trans- 
formed  by  the  virus,  and  such  cells  develop  into  fatal 
lymphomas in susceptible hosts (11-13). EBV is maintained 
in its target cell as a nonintegrated, 180-kb episomal plasmid. 
In growth-transformed B cells the virus stays latent and trans- 
formed B cells enter lytic cycle with production of infectious 
virus progeny rarely at best (14). Latency of stable, growth- 
transformed B lymphoblasts is characterized by the expression 
of viral  proteins, Epstein-Barr nuclear antigens (EBNAs) 1 
-1, -2, -3a, b, and c, latent membrane protein (LMP-1),  and 
terminal protein (TP)2a,b (LMP-2A/B)  (15). 
Binding of EBV to the CD21 cell surface receptor starts 
two series of events that initially proceed independently al- 
though both are critical for subsequent growth transforma- 
tion. A cellular  activation cascade of postreceptor binding 
events includes calcium and proton currents and the induc- 
tion of tyrosine kinase and stress proteins (16-18). Interference 
with any of these events prevents transformation, generating 
viable, principally transformable cells that harbor competent 
virus without undergoing growth transformation (16). 
I Abbreviations used in this paper: ds, double stranded; EBNA, Epstein-Barr 
nuclear antigen; h, human;  RNA  i~  EBV-induced B cell RNA; RNA  c~ 
common B cell RNA; RT,  reverse transcriptase;  v, viral. 
The second series of events, viral latency gene expression, 
immediately follows circularization and translocation of the 
linear virus genome to the nucleus.  Transcripts  of at least 
four latency genes (EBNA-1 and -2, and LMP-1 and -2) are 
detectable within 30 min of infection (16, 19). Transcription 
is independent of the cellular activation cascade but intimately 
regulated; the transient suppression of any one of these genes 
by antisense reagents aborts expression of all others and pre- 
vents subsequent growth transformation (19). 
It is still unclear how and when these two chains ofpostin- 
fection sequelae combine into the events that initiate transi- 
tion to and then sustain the growth-transformed phenotype. 
We have argued that these events are most likely associated 
with the transient or permanent activation of genes devoted 
to the regulation of cell growth, and we chose a subtractive 
molecular approach as a strategy for their identification. Here 
we describe the construction of a cDNA library  highly en- 
riched for genes expressed in B cells infected with EBV for 
6 h, and report IL-10 as the first transformation prerequisite 
gene identified by our strategy. 
Results of a first, random sampling of clones obtained after 
subtraction were unexpected. Sequencing identified the viral 
BCtLF1 gene, a sequence highly homologous to the human 
IL-IO gene (20). The BCRF1 (viral[v] IL-10) gene had been 
characterized as a "late" viral gene expressed during the lytic 
phase of virus replication (21) and it shares most functions 
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sion of IL-2 and IFN-y production as well as potent B cell 
growth-promoting activity (23-28).  We now demonstrate 
that vlL-10 is expressed early during the transformation pro- 
cess, preceding the expression of cellular human (h)IL-10 by 
20-30 h, and that both continue to be expressed  in estab- 
lished EBV-transformed cell lines. As the transient suppres- 
sion of vlL-10 expression  by short-lived antisense reagents 
aborted subsequent transformation, our data establish  vlL- 
10 as a new, bona fide latency gene whose function is critical 
for at least the initiation and perhaps the maintenance of the 
transformed phenotype. 
Materials  and Methods 
The preparation of  purified, largely resting B lymphocytes from 
tonsil and of B95-8 strain EBV transformation as well as cell cul- 
ture conditions have been described previously (17). B cells were 
infected with virus (10  s particles/3  ￿  106 cells) and total RNA 
was prepared by the guanidine thiocyanate method (29) either im- 
mediately (common B cell RNA [RNAc~  or after 6 h of cul- 
ture  (EBV-induced B cell RNA [RNAina]). Poly(A) RNA was 
purified using oligotex-dT30 latex beads (gift from Japan Rosch 
Inc., Tokyo,  Japan), which carries covalently surface-bound oligo- 
nucleotide chains of the structure d(G)10d(T)30 (30). Total RNA 
(500/~g/tube) was mixed with 1% (wt/vol) of the oligotex-dT30 
beads in 1 ml elution buffer (10 mM Tris-HC1, pH 7.5, 1 mM 
EDTA, 0.1% SDS), incubated (65~  for 5 min), and cooled. After 
addition of NaC1 (to 100 mM), the beads were held at 37~  for 
10 min, spun, washed twice (10 mM Tris-HC1, pH 7.5, 1 mM 
EDTA, 0.1% SDS, 0.1 M NaC1), and resuspended in 400/~1 of 
water. Bound mRNA was eluted at 65~  into the supernatant and 
precipitated with 2 vol of cold ethanol. 
Solid-Phase eDNA '~  Library.  After hybridization of purified 
poly(A)  RNA  (20  #g)  from  resting  B  cells (mRNA  c~  to 
oligotex  beads, covalently  bound cDNA was synthesized  with AMV 
reverse transcriptase (RT) (1,000 U, 42~  min; BRL, Burling- 
ton, Ontario, Canada), exploiting as primers the covalent d(T)30 
tails of the beads resuspended  in reaction buffer (100 mM Tris-HC1, 
pH 8.3, 100 mM KC1, 10 mM MgC12, 2 mM each dNTP, 20 mM 
2-ME, 500 U/ml of RNasin,  500 #g/ml BSA) (30). After heat 
denaturation  (92~  min),  the  cDNAc~  con- 
jugate was spun and washed to remove RNA, and resuspended 
in 100 #1 of TE (10 mM Tris-HC1, pH 8.0,  1 mM EDTA). 
Subtraction ofmRNA ina.  1/~g of mRNA  ina was incubated (10 
min/55~  with 5 #g oligo-dTx2-1s, and the cDNA  ....  oligotex 
conjugate (100 #1) was incubated with 50/~g of oligo-dA~lG10. 
Both were then mixed and held at 55~  for 10 min in a total reac- 
tion volume of 500 ~1 elution buffer with 0.1 M NaC1. Reaction 
tubes were spun, supernatants  recovered, and the pellets resuspended 
in 500/~1 of TE, denatured (75~  min), and washed to remove 
bound RNA to regenerate the single-stranded (ss)-cDNA  ~~  li- 
brary for subsequent subtraction cycles. The subtraction efficiency 
during several cycles was measured by densitometry of slot blots 
hybridized to radiolabeled  B-actin (common cellular) and EBNA-2 
(viral latency gene) probes, controlled by RT-PCR amplification 
with fl-actin and EBNA-2 oligonucleotides (31). 
After four subtraction cycles of mRNA  ~"d, ss-cDNA was syn- 
thesized (37~  min) with Moloney murine leukemia virus 
(MMLV) RT (200 U; BILL) in 50 mM Tris-HC1 (pH 8.3) con- 
taining 75 mM KC1, 3 mM MgClz, 1 mM each dNTP, 10 mM 
DTT, and 80 U RNasin followed by generation of second-strand 
cDNA (16 h/14~  in the presence of 20 U/ml RNase H, 500 
U/ml Escherichia cell DNA polymerase  I, and 100 U/ml E. cell DNA 
ligase (New England Biolabs, Mississauga, Ontario). After gener- 
ation of  blunt ends (370C/45 min in 100 ng/ml RNase A, 50 U/m1 
RNase H, 250 U/ml E. cell DNA ligase, and 100 U/ml T4 DNA 
polymerase), EcoRI  adapters were added and  1-10-kb double- 
stranded (ds)-cDNA fragments were recovered from a 1% low 
melting agarose gel. Recovered  ds-cDNA fragments were ligated 
to EcoRI-digested Xgtl0 arms and then packaged into ~ particles 
(Amersham, OakviUe, Ontario). After phage infection of E. cell 
NM514 and overnight culture on H-medium plates, plaques were 
transferred  onto  Hybond-N  §  (Amersham  Corp.,  Arlington 
Heights, IL) and hybridized to random-primed 32p-cDNA derived 
from: (a) mRNAr176 (b) mRNAi*d; and (c) a series of end-labeled 
oligonucleotides  derived from EBV and cellular genes (see below). 
A normal tonsil (Xgt-11) library was obtained from American Type 
Culture Collection (RockviUe, MD) (37546) as a control. 
DNA  Sequencing.  DNA sequencing by primer extension was 
carried out with fluoresceinated  hgtl0 forward (5'-FAM-AGCAAG- 
TTCAGCCTGGTTAAG)  and reverse (5'-FAM-CTTATGAGTATT- 
TCTTCCAGGGTA) primers using the dideoxy-AutoRead  TM Se- 
quencing kit (Pharmacia, Mississauga,  Ontario) as instructed. Ter- 
minated samples were analyzed  on an automated laser fluorescence 
(A.L.F.  TM) automated DNA sequencer following protocols of the 
manufacturer (Pharmacia). 
PCR.  Standard, 30-cycle  PCR used primers from the EBV and 
cellular gene sequences previously described (8) in addition to re- 
agents for amplification  of  vlL-10 (32) and lilbl0 (22): vlL-10-9681, 
5'-CGAAGGTTAGTGGTCACTCT; vlb10-10186(A),  5'-CAC- 
CTGGCTTTAATTGTCATG; hlL-10-940, 5'-CGCTTTCTAGCT- 
GTTGAGC~ hlL-10-1400(A), 5'-CACTGC~CTTCCATCTCCT. 
Internal oligonucleotide probes were vlL-10-9921, 5'-TACCTG- 
GAGGAAGTCATGCC; and hlL-10-1277(A), 5'-CACCATGTT- 
GACCAG~TT.  Numbers indicate  the 5' position in the EBV 
genomic sequence (33) and hlbl0 (22). RT-PCR amplifications 
were controlled by omission of RT;  these reactions as well as 
template-free  water controls were negative. Oligonucleotides were 
synthesized on a GeneAssembler Plus  TM instrument according to 
supplied protocols (Pharmacia). 
B Cell Transformation Studies.  The transformation of fresh ton- 
sillar B cells was examined  as described (17). Briefly,  purified B cells 
(3-5  x  106) were exposed to los B95-8 strain EBV particles, in- 
cubated (90 min/37~  in HL/1 medium (Ventrex, Portland, ME) 
until distributed into microcultures (10  s cells/well). Where indi- 
cated, fresh lymphocytes  were first loaded with 20mer sense or an- 
tisense oligonucleotides (1/zg)  during a 2-h incubation (17). In 
some experiments 10 U/well of recombinant hlL-10 (gift from Dr. 
K. Moore, DNAX, Pale Alto, CA) was added at the beginning 
of culture. Cultures were maintained until supernatants were re- 
moved 2 wk later. Transformation was assessed as clonal expan- 
sion, measuring cell  growth with an automated, fluorescence-based 
procedure (16), or by measurement of secreted Ig, using a particle 
concentration fluorescence  immunoassay technique (17). We pre- 
viously found good correlation between both approaches (18). 
Results 
Subtraction  Library.  We used the detection of a house- 
keeping gene (fl-actin) and of IgM (C/z heavy chain gene) 
to assess the efficiency of our cDNA subtraction procedure. 
Densitometer scans of RNA slot blots hybridized to a B-actin 
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offl-actin and EBNA-2 fragments. 
Equal volumes of ds-cDNA from 
before and after subtraction were 
amplified  with fl-actin or EBNA-2 
primers,  and the PCK product 
was hybridized to 32p end-labeled 
internal reporter probes. The EBV- 
transformed B cell line 2D5 was 
generated in our laboratory  and 
served as a control. 
probe showed a 50% reduction of signal after the first sub- 
traction cycle and >90% reduction after the second. There- 
after the signal was lost. Northern gel hybridization detected 
fl-actin transcripts in mRNA  c~  but not in 4 x  subtracted 
mKNA  ~a, and we therefore used P,T-PCK (30 cycles) to de- 
tect less prevalent  species (Fig.  1). fl-Actin sequences were 
amplified in both P,  NA samples but only faint hybridization 
signals  were  obtained  with  PCR  products  of  reverse- 
transcribed mKNA  ~a. 
EBV latency gene transcripts are not detectable by Northern 
blot hybridization until several days after infection (34),  al- 
though latency gene transcription of at least four of the latency 
genes begins as early as 30 min postinfection and is a critical 
transformation prerequisite (19). Transcripts of EBNA-2 (Fig. 
1), EBNA-1, and the LMPs (not shown) were easily detected 
by RT-PCR of mKNA  i~d, both before and after  4 x  sub- 
traction. These data suggested a reasonable efficiency of the 
subtraction process: we estimate that 0.5% of common genes 
in RNA  ~~  remain after 4 x  subtraction, although these spe- 
des make up the vast majority of transcripts in RNA  ~'m. On 
the other hand,  *70%  of transcripts specific for RNA  ina 
were still present after  subtraction. 
This was confirmed after cloning of subtracted ds-cDNA. 
We obtained a total of ",~2 x  10  s recombinant phage. Repli- 
cate nylon membrane lifts from plates containing 1,600 recom- 
binant clones each were hybridized with randomly primed 
and labeled  mRNA  c~  or mRNA  ina (Fig.  2).  About  15% 
of phages hybridized with the RNA  .... probe" while 78% 
hybridized with the RNA  ind "probe"  (Table 1).  1 out  of 
3,200 phages hybridized with an IgM probe and none hy- 
bridized with B-actin.  We recently reported that EBV in- 
duces the cellular  genes p56-kk, hsp70, and hsp90 early in 
the  transformation process  (17, 18). Recombinant clones 
hybridizing to lck and hsp70 probes were identified at a fre- 
quency of 0.25 and 1.3%, respectively. When we used similar 
conditions to analyze a normal tonsil cDNA library in Xgt- 
11 (3,000 recombinant phage) as a control, we found 0.53% 
of clones  hybridizing with the IgM and 0.26%  with the 
B-actin probes.  None of the plaques hybridized to the lck 
probe and one plaque hybridized to the hspT0 probe. 
Gene Induction after EBV Infection.  The above data indi- 
cated that the subtraction library generated from RNA ind 
showed reasonable enrichment for transcripts induced in fresh 
human B lymphocytes  within 6 h of EBV infection. We ran- 
domly chose 21 phages grown at very low density, amplified, 
and  used  PCR  with  flanking,  Xgtl0-derived  primers  to 
generate sufficient DNA template for sequence analysis. Flu- 
orescein end-labeled primers were then used for direct dideoxy 
sequencing and subsequent analysis on the A.L.F.  TM  auto- 
mated DNA  sequencer. 
In six clones no PCR product was generated, and in four 
clones the fragment size was <200 bp. One clone each con- 
tained EBNA-1 and EBNA-2 sequences, one contained a par- 
tial coding sequence of CD19, and another of glucose-6-phos- 
phate reductase. CD19 transcripts are of potential interest as 
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Figure 2.  Plaque  hybridization 
of a subtraction  library. Approxi- 
mately  1,600 recombinant phages 
each were plated on two 137-mm 
dishes.  Replicate  lifts  on  nylon 
membrane  filters were probed with 
randomly  primed,  32p-labeled 
cDNA made from: (A) mKNA  ~~ 
or (B) mR.NA  ind. Table  1.  Plaque Hybridization of Subtraction and Standard 
B  Cell Libraries 
Library 
Probes 
Total plaques*  cDNA  ~176 cDNA  ind  IgM  /3-Actin 
Subtraction  3,200  486  2,500  1  0 
Tonsil  3,000  2,800  ND  16  8 
Subsets of two cDNA X libraries (see text) were hybridized with radio- 
labeled cDNA obtained from purified, fresh human B lymphocytes  that 
had been infected  with EBV for 0 (c.DNA  r176 or 6 h (cDNA~na).  Labeled 
probes for the human C# heavy  chain (IgM) or the human/3-actin gene 
were used in addition. Numbers refer to plaques that hybridized to the 
respective probes. 
* Combined data from two independent plates. 
this molecule plays a dual role in B cell function, triggering 
positive or negative signals depending on preceding or coac- 
tivation  events  (35).  Somewhat unexpectedly,  three clones 
contained sequence stretches highly homologous (82-87%) 
to different cytochrome p450 genes: to our knowledge, this 
enzyme  system has  not previously been associated with  B 
cell transformation. The full sequence characterization  of these 
clones is in progress. However, we were surprised to obtain 
one sequence identical to the BCtLF-1 reading frame in the 
EBV genome. This is a late gene expressed during the lytic 
phase of virus replication  and therefore not expected in la- 
tently infected B lymphocytes. BCRF1/vlL-10 shows a high 
degree of homology to the hlL-10 gene, with which it shares 
most,  albeit  not  all,  functions  (reviewed in reference 22). 
Concerned  that  the  BCtLF1  clone  might  represent  a 
genomic, EBV-derived done, or that by accident the B cell 
donor was undergoing  an unrecognized,  acute EBV infec- 
tion  or  EBV-driven  lymphoproliferative  disease  (12),  we 
decided to further pursue this observation. Although we had 
previously (as expected) found no evidence for the expression 
of late EBV genes early during transformation  (17,  19), we 
now used PCR and found that neither the original RNA  c~ 
nor  the  RNA  ind  or  the  subtracted  library  contained  se- 
quences coding for gp350/220,  a late viral  (envelope) pro- 
tein (33) (data not shown).  As well, we used several previ- 
ously designed oligonudeotide probes derived from intron 
regions in the EBV genome (19) and found no phages that 
hybridized among 3,200 tested. In contrast,  12 recombinant 
phages hybridized  to  a vlL-10 oligonudeotide  probe. 
vlL-lO  Expression during  B  Cell  Transformation.  PCR 
primers  and  probes  were  designed  for  the  differential 
amplification and hybridization of either h- (cellular) or vlL- 
10.  Only the latter system amplified a correctly sized frag- 
ment from a vlL-10 cDNA (22) (gift from K.  W.  Moore, 
DNAX  Research  Institute,  Inc.),  while  only  the  former 
amplified a hlL-10 sequence from mitogen-activated blood 
lymphocytes (not shown). Purified B cells were infected with 
EBV, RNA was prepared 2-120 h after infection,  and amplified 
with  vlL-10,  hlL-10,  or 13-actin RT-PCR systems. 
As shown in Fig.  3, freshly EBV-infected human B ceils 
begin expression of vlL-10 within 4-6 h of infection.  Con- 
sistently, no transcription of the cellular hlL-10 gene was de- 
tectable 12-18 h  after infection,  but easily detectable levels 
of hlL-10 transcripts  are present at and beyond 1 d into the 
transformation process. Comparable amplifications were ob- 
served for cellular/3-actin  in  all  samples. 
Control reactions were performed with a number of dif- 
ferent cell lines.  The EBV-negative T cell line Jurkat (17) did 
not express vlL-10 or hlL-10.  In contrast,  all of nine EBV- 
transformed cell lines generated previously in our laboratory 
expressed both vlL-10 and hlL-10 (e.g.,  2D5; Fig. 3). vlL- 
10, but not hlL-10, transcripts were amplified in RNA from 
the B95 (marmoset)  cell line (33),  consistent with  a poly- 
morphic  sequence of the cellular gene in this  species.  The 
EBV-producing human P3HR1 line was consistently posi- 
tive for vlL-10 and hlL-10 expression.  Taken  together,  our 
observations characterize  vlbl0 as bona fide EBV latency gene 
that is regularly expressed before and then in addition to hlL-10 
in  EBV-infected B  lineage cells. 
vlL-lO Functions in the Transformation Process.  We have pre- 
viously used antisense oligonudeotides to determine if genes 
Figure 3.  Expression  of vlL-10 and hIL-10 in freshly EBV-infected  B 
lymphocytes  and in several  control cell  lines. Poly(A)  KNA was prepared 
at various  times  after  infection  of  fresh  B ~lls or from  exponentially  growing 
cell lines. KT-PCK used primer pairs that distinguish the two Ibl0 spe- 
des. PCK products were separated and probed with 32p end-labeled in- 
ternal oligonucleotides. 
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Name*  Sequence 
vIL-10  -  20 
vIL-10 (A)  -  1 
vIL-10  61 
vIL-10 (A)  80 
vIL-10  502 
vlL-10 (A)  521 
hlL-10  31 
hlL-10  (A)  50 
hIL-10  112 
hIL-10  (A)  131 
hIL-10  921 
hlL-10  (A)  940 
TAGGCCTGCACACCTTAGGT 
ACCTAAGGTGTGCAGGCCTA 
TGTGGAGGTACAGACCAATG 
CATTGGTCTGTACCTCCACA 
AAAGCCAGGTGATAATTCCA 
TGGAATTATCACCTGGCTTT 
ATGCACAGCTCAGCACTGCT 
AGCAGTGCTGAGCTGTGCAT 
AACAGCTGCACCCACTTCCC 
GGGAAGTGGGTGCAGCTGTT 
TCCATTCCAAGCCTGACCAC 
GTGGTCAGGCTTGGAATGGA 
* A, antisense sequences. Numbers represent the 5' position of oligonucleo- 
tides  on the sense strand. 
expressed early after EBV infection played a direct role in the 
transformation process (17, 19). The same strategy was used 
to determine if vlL-10 subserved any role in the transforma- 
tion process, not a foregone conclusion since strong hlL-10 
expression is observed within 1 d of virus infection. Conven- 
tional sense and antisense oligonucleotides were synthesized 
from h- and vlL-10 regions identified in Table 2.  Aliquots 
of fresh B lymphocytes were loaded with one of these re- 
agents each, infected with EBV, and transformation was mea- 
sured 2 wk later (17). 
As shown in Fig. 4, vlL-10 antisense, but not sense, oligo- 
nucleotides reduced transformation to essentially background 
levels. In the experiment shown the Ig secretion of antisense 
oligonucleotide-treated cells approached that of unstimulated 
B cells. Similar results were obtained when clonal expansion 
was assessed by measurement of cell growth. The half-life 
time of these oligonucleotides is '~6 h  (17,  19), and it was 
not surprising that reagents directed at hlL-10 transcripts were 
ineffective, as our above results determined that hlL-10 is ex- 
pressed a full 1 d  later than vlL-10. 
To determine the mode of action of vlL-10 antisense oli- 
gonucleotides, we examined levels ofvIL-10 transcripts. Freshly 
prepared B lymphocytes were incubated with sense (vIL-10 
502) or antisense (vIL-10 [A] 521) oligonucleotides as above. 
RNA was extracted from 6-h postinfection cells and treated 
with  DNaseI.  ss-cDNA  was  synthesized with  oligo(dT) 
primer from 500 ng of bulk RNA, and ",~5 ng of ss-cDNA 
was amplified by RT-PCR (30 cycles), vlL-10 gene transcrip- 
tion was dramatically inhibited in RNA from antisense-treated 
cells while there was no effect of this treatment on 8-actin 
transcription levels (Fig. 5). The antisense effect was specific, 
since levels of EBNA-2 transcripts,  which show a comparable, 
low abundance as vIL-10 transcripts, were unaffected  by vIL-10 
antisense oligonucleotides. Titrations of template concentra- 
tions indicated that the amplification of B-actin fragments 
was well below saturation level in our PCR system (data not 
shown). 
While sense/antisense oligonudeotide effects showed clear- 
cut sequence/strand specificity, we tested a number of addi- 
tional reagents.  Sense and antisense oligonucleotides were 
added at the time of EBV infection to cultures of purified 
B lymphocytes. Targeting of several coding regions of IgG, 
IgM, or IgA heavy chain transcripts did not affect transfor- 
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Figure 4.  vlbl0 antisense oligo- 
nucleotides  abort  transformation. 
Purified fresh B lymphocytes  were 
loaded with various sense ([3) or an- 
tisense (i) oligonucleotides before 
EBV infection  and culture.  The 5' 
positions  of these oligonucleotides 
on the sense strand  of the respec- 
tive rib10 or hill0 sequences are 
indicated below the graph (see Table 
1). Controls (g~) received  EBV alone 
or  no  virus.  Transformation  was 
measured as virus-induced Ig secre- 
tion  (left) or  cell  growth  (viable 
cells/ml; right) 2 wk later. Figure 5.  Effect of antisense 
oligonucleotides on transcription 
levels of vlL-10, EBNA-2,  and 
/3-actin. Purified fresh B lympho- 
cytes were incubated with sense 
(vIbl0 502) or antisense (vlbl0 
[A] 521) oligonucleotides as be- 
fore.  RNA  was  prepared  from 
6-h  postinfection  cells for  RT- 
PCR.  Amplification  products 
were  separated and  probed  as 
before. 
marion rates,  nor the EBV-induced Ig secretion detected at 
the end of culture. Similarly, sense and antisense oligonucle- 
otides derived from the B-actin sequence had no effect on 
EBV-induced transformation, nor did targeting of the late 
viral gene gp350/220  (data not  shown). 
We then asked whether the observed vlL-10 requirement 
in the transformation process had an endogenous mode of 
action, whether it functioned in autocrine fashion through 
receptor interaction, and whether the effect showed biospecifi- 
city. These experiments were done using recombinant hiL- 
l0,  as the viral product was not available  to us.  However, 
vlL-10 and hlL-10 share most functional activities,  including 
receptor binding (22, 28, 36). As shown in Table 3, the dis- 
rupted transformation process in antisense-treated cells could 
be fully rescued by addition of exogenous (h)IL10. The vlL- 
10 antisense effects therefore showed the expected biological 
specificity and this function appears to resemble an autocrine 
mechanism likely involving receptor interaction.  An effect 
of exogenous IL-10 was only observed in the vlL-10 antisense- 
treated cells,  and the IL-10 mediated rescue of transforma- 
tion did not reflect a general growth-promoting effect. Taken 
together, these findings establish a critical role for vlL-10 tran- 
scription very early in the transformation process. 
Discussion 
In this report we have used an effective procedure for the 
generation of a subtraction cDNA library towards the identi- 
fication of a gene, newly discovered to be a transformation 
prerequisite. The subtraction library contained vlL-10 tran- 
scripts and subsequent functional studies showed clearly that 
vlL-10 is not a late viral gene expressed only during the lytic 
phase of virus replication, but represents a true latency gene 
(37),  expressed very early in the transformation process as 
well  as  in  latently  infected  cells  with  stable,  growth- 
transformed phenotype (38). 
vlL-10, i.e.,  the BCRF1  open reading frame in the EBV 
genome, was shown in 1990 (20) to contain a sequence highly 
homologous to hlL-10.  This was an intriguing finding as 
IL-IO has functions highly consistent with survival and propa- 
gation of a B-lymphotropic transforming virus. Viewed as 
the agent that directs immune responses towards either mainly 
cellular (T lymphocyte mediated) or humoral effector prin- 
ciples,  IL-10 directly and through accessory cells (25) inter- 
feres with IL-2 and IFN-qr  production (26,  27) but acts  as 
a potent (28)  B cell growth factor (39,  40),  and it may be 
the active principle behind apparent suppressor cell phenomena 
(24).  It was primarily IL-10's ability to interfere with IFN-qr 
production and T effector cell generation that painted an ap- 
pealing scenario for the escape of a virus-infected B cell from 
T cell surveillance,  in particular after it was determined that 
vlL-10 shared many relevant functions with the full human 
molecule (22). 
Our data do not detract from the possible role of IL-10 
in the escape of EBV-infected B cells from T cell surveillance, 
and given the tremendous potential of EBV-infected cells to 
rapidly develop into aggressive lymphomas (11, 12, 41-43), 
this  remains an important  area  of research.  However, our 
findings add a new dimension to IL-10 and its viral homo- 
logue, since vlL-10 now appears  as a true latency gene with 
a specific, critical role in the growth transformation process 
itself. 
To study genes that play critical roles during the initial 
transformation events, we have previously used short-lived, 
conventional sense and antisense oligonucleotides with half- 
lives of '~6 h (17). These experiments showed that the tran- 
sient impairment of specific viral and cellular transcripts can 
effectively abort subsequent transformation, even though com- 
petent virus is harbored in perfectly transformable,  viable cells. 
This strategy is able to delineate critically timed gene expres- 
sion events, and we demonstrated the closely interactive, con- 
Table  3.  Rescue  of Antisense-inhibited Transformation by Exogenous IL-IO 
EBV  +  vlL-10 oligonucleotides  +  hlL-10 oligonucleotides 
Cytokine  Unstim.  EBV  -  20  (A)  -  1  502  (A) 521  112  (A) 121 
None  290  1,340  1,116  458  1,118  523  919  1,023 
hlL-10  320  1,159  1,212  1,132  1,233  1,140  1,042  1,058 
Cell growth ( x  103) of EBV-infected cells after 12 d of incubation. Sense or antisense (A) oligonucleotides derived from the v- or hlL-10 coding 
sequence (see Table 2) were added as indicated.  Cultures received either  no or 10 U/ml of recombinant, hlL-10.  Unstim., no EBV added. 
444  Viral Interleukin 10 Expression by Epstein-Barr Virus certed fashion that characterizes the regulation of gene ex- 
pression for four such genes (19). 
The exact functions of those viral latency genes that were 
identified as critical in the early transformation process are 
largely but  not entirely uncertain.  EBNA-1  acts  in c/s by 
binding the virus' latent origin of replication (off-P) to main- 
tain the virus circular genome in its episomal locale (44). 
LMP-1, at least in some target cells (45, 46), activates,  in 
trans, the cellular protooncogene, bcl-2 (47), which may pre- 
vent apoptosis in cells susceptible to this process (48).  Since 
essentially all infected B cells undergo early virus-induced ac- 
tivation events but <10% reach stable transformation, there 
must be B cell-inherent protective mechanisms that interfere 
with transformation. Apoptosis is a candidate mechanism in 
this process, perhaps as a result ofpost-EBV receptor binding 
events that represent a typical, if to considerable extent, EBV- 
specific activation cascade with calcium and proton currents 
as well as tyrosine kinase and stress protein induction (16-18). 
The addition of IL-10 to the emerging map of early steps 
in the transformation process is likely important because of 
the direct B cell growth-promoting function of the molecule 
(28),  and it will be interesting to define its cellular target 
functions in newly infected B lineage cells. The advantage 
provided  to  an  ancient  EBV  mutant  that  "acquired"  a 
(processed) copy of human IL-10 is surely significant if the 
gene enhances the primary transforming capacity of the virus. 
In this sense, escape from T cell surveillance may indeed be 
of lesser relevance as suggested by the fact that ~90% of the 
adult population carries the virus but few succumb to pri- 
mary EBV +  B  cell  lymphoma  unless  there  is  a  serious 
deficiency of immunocompetence (12,  13). 
Our observations of the sequential expression of v- and 
then hlL-10 are intriguing. The experiments with antisense 
olignnucleotides as described here could not address the func- 
tional role of hlL-10 in the transformation process, but studies 
are under way with long-acting, stable phosphothioate oli- 
gonucleotides (49). It will be important to determine if there 
is a direct link between vlL-10 and hlL-10 expression, per- 
haps analogous to the bcl-2 transactivation by the LMP-1 
latency gene (47). Interestingly, there is an EBV homologue 
of cellular bcb2 in the BHRF1  reading frame (50). 
The effectiveness of short-lived antisense oligonucleotides 
demonstrates that early EBV gene expression events show 
critical timing. While the expression of EBNA and LMP tran- 
scripts is closely linked and begins very quickly after infec- 
tion (18), the IL-IO effect is required several hours later and 
targeting of IL-IO does not directly affect expression of the 
earlier latency genes. One attractive model derived from these 
data is the initiation of growth transformation by a fine-tuned 
barrage of quasi-cellular proteins, expressed out of context 
of the normal regulation of  ceUular gene expression and growth 
control. It is perhaps the sequence and timing of such "signals" 
that avoid triggering of normal cell growth control mecha- 
nisms while still  driving the cell towards the first of con- 
tinuous cell cycles. 
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